Table 5 Immunological, demographic and clinical parameters in the two groups of patients with or without graft dysfunction (eGFR<60ml/min/1.73m²) one year after transplantation

FOXP3

Baseline ^a

1.590 (1.408-1.823)

1.520 (1.295-1.678)

0.033

15 days^a

1.270 (0.999-1.520)

1.125 (0.510-1.435)

0.156

60 days^a

1.270 (0.970-1.398)

1.160 (0.940-1.430)

0.952

One year^a

1.420 (1.280-1.660)

1.215 (1.015-1.363)

0.055

flCTLA-4

Baseline^a

0.850 (0.623-1.060)

0.825(0.580-0.980)

0.713

15 days^a

0.610 (0.365-0.845)

0.550 (-0.020-0.740)

0.072

60 days^a

0.620 (0.443-0.870)

0.645 (0.285-0.913)

0.763

One year^a

0.890 (0.2800-1.290)

0.740 (0.640-0.800)

0.790

solCTLA-4

Baseline^a

0.240 (0.105-0.443)

0.280 (-0.125-0.508)

0.457

15 days ^a

-0.050 (-0.225-0.340)

-0.190 (-0.700-0.260)

0.039

60 days^a

0.145 (-0.008-0.370)

0.090 (-0.230-0.330)

0.559

One year^a

0.500 (-0.06-0.633)

0.100 (0.005--0.318)

0.402

Recipient gender (M/F)

37/50

25/36

0.825

Donor gender (M/F)

29/50

27/36

0.161

Recipient age ^b

55.7±10.4

47.4±11.3

0.0002

Donor age ^b

57.9±12.6

40.6± 15.1

<0.0001

Induction:

- Basiliximab (%)

48/50 (96.0)

31/36 (86.1)

 0.124

- Anti-thymocyte globulins (%)

2/50 (4.0)

5/36 (13.9)

CNI (cyclosporine vs. tacrolimus)

10/50 (20.0)

4/36 (11.1)

0.378

mTORi (%)

8/50 (16.0)

4/36 (11.1)

0.754

HLA mismatches^b

3.1±1.1

3.0±1.5

0.785

Class I PRA (%)

14/50 (28.0)

19/36 (52.8)

0.035

Class II PRA (%)

10/50 (20.0)

14/36 (38.9)

0.092

Time on dialysis (months)^b

58.4±36.9

46.4±26.4

0.160

Cold ischemia time (min)^b

632.4±294.1

620.2±227.4

0.836

Warm ischemia time (min)^b

43.1±14.0

44.8±11.1

0.175

Previous transplants (%)

5/50 (10.0)

1/36 (2.8)

0.394

Maintenance therapy change (%)

13/50 (26.0 )

6/36 (16.7)

0.443

Proteinuria at one year (mg/l)^b

159.9±180.4

148.2±156.8

0.564

DSA development (%)

12/50 ( 24.0)

7/36 (19.4)

0.811

DGF (%)

21/50 (42.0)

10/36 (27.8)

0.260

CMV reactivation (%)

13/50 (26.0)

8/36 (22.2)

0.457